NTRK gene fusions

Home/Tag: NTRK gene fusions

Important Research Study Holds Hope for “Quadruple Wildtype” GIST Patients

A recent study published in the Journal of Translational Medicine, presents important research findings for the 10-15% of GIST patients who lack mutations in KIT, PDGFRA, SDHX or RAS pathway indicators, the primary oncogenic [...]

By |2018-10-30T09:25:15-04:00January 6th, 2017|News, Research|

Loxo Oncology Announces Plans for LOXO-101

In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. [...]

By |2020-02-21T15:03:40-05:00December 22nd, 2016|Clinical Trials, News, Research|

LOXO-101 receives breakthrough therapy designation from FDA for solid tumors with NTRK gene fusions

Loxo Oncology  announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of unresectable or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusions. This [...]

By |2020-02-21T14:56:38-05:00July 21st, 2016|News, Research|

LOXO-101 Holds Promise as Potential Treatment Targeting Solid Tumors

A recent announcement from the University of Texas MD Anderson Cancer Center described a study that shows promise for a potential treatment (LOXO-101) that targets solid tumors with NTRK gene fusions. The investigational agent, [...]

By |2018-10-30T09:50:34-04:00May 19th, 2016|News, Research|
Go to Top